Sequencing Senior Sales Specialist, Milan, Italy

Life Technologies
Job Location: 
Milan, Italy
Excellent Package

Excellent Benefits

Job Description: 

Sequencing Senior Sales Specialist - Milan

This is a field based positon focusing on the Lombardy / Piedmont territories

Language requirements - Fluent English and Italian language skills

Preferred home location: Milan

Please submit applications in English

Molecular biology / NGS sales experience is essential to be considered for this role.

The role of Sequencing Sales Specialist is to drive Sequencing Sales for Next Generation Sequencing e.g. Ion Torrent and SOLiD in Italy . The role holder will use their knowledge of the business and external context to commit to and deliver profitable initiatives that build sales. The role holder will be responsible for implementing sales strategy and tactics for related product lines and applications to achieve sales figures.

Major Responsibilities
The major responsibilities are to:
Achieve the agreed sales target.
Increase the install base of Life Technologies Instrumentation within the sales territory (PGM, SOLiD)
Work together with local sales colleagues and manager sales to ensure all possible actions are done in order to secure business in competitive situations.
Drive business expansion in collaboration with Support, Sales and Market Development.
Build up reference sites as required.
Set up and undertake complex negotiations.
Review effectiveness or negotiation strategy on a continual basis.
Benchmark own sales techniques against best practice.
Coach sales colleagues and ensure transfer of knowledge, experience and best sales practice.
Sales Forecasting Anticipate pipeline changes and has plans in place to address shortfalls. See trends and coordinate sales activities with sales manager accordingly


Qualification / Experience:
Academic degree (minimum MSc) in scientific disciplines ´
Relevant Sales experience and a high level of professional expertise gained in the sale of CapEx lab instrumentation Relevant technical and scientific background. (Next Generation Sequencing knowledge is essential)
A track records of closing high value deals in highly competitive situations.
Able to develop and implement strategies that drive growth.
Good verbal and written command of the Italian and English (technical) language.
Able to undertake frequent travel. There is the possible need to participate in congresses over weekends.

Skills / Behaviours :
Strong teamwork skills able to align across teams and organisations and fosters collaboration.
Establishes stretch goals and drives for results.
Able to take responsibility by holding self accountable for personal delivery.
First class negotiating skills, able to influence in highly competitive market space and work proactively to differentiate and promote the benefits of the LT portfolio and close deals.
Solid organisational skills and ability to set priorities and manage time effectively.
The ability to challenge the status quo and drive continuous improvement.
Strong communication skills and the ability and willingness to be flexible and adaptable to work in a complex cross-functional environment

Contact Information: 

Scott McPherson
Talent Acquisition Manager, Southern Europe and Emerging Markets, EMEA |
phone +44 141 814 6021 • mobile +44 7534 698 758 •
102 Fountain Crescent • Inchinnan Business Park • Paisley • PA4 9RA • United Kingdom

About Our Organization: 

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.